View Older Stories View More Recent Stories
-
Illumina (ILMN) and Tempus (TEM) partner to drive the future of precision medicine through genomic AI innovation
-
Tempus AI (TEM) to acquire Deep 6 AI
-
Stifel Reiterates Hold Rating on Tempus AI Inc (TEM)
-
Tempus AI (TEM) Files for 4.84M Share Offering by Selling Stockholders
-
JPMorgan Downgrades Tempus AI Inc (TEM) to Neutral
-
After-hours movers: Zoom, Hims & Hers Health, Tempus AI, and more
-
Tempus AI, Inc (TEM) Reports Q4 Loss of $0.18
-
Tempus AI (TEM) call put ratio 1.6 calls to 1 put into quarter results and outlook
-
Tempus AI (TEM) call put ratio 1.4 calls to 1 put into quarter results
-
Tempus AI (TEM) call put ratio 2.3 calls to 1 put into quarter results
-
Tempus AI (TEM) and Stemline Therapeutics Collaborate to Implement Tempus Next
-
Tempus AI (TEM) call put ratio 1.9 calls to 1 put into quarter results
-
Ares Management (ARES) provides Tempus with total debt package of $560 million
-
Increasing unusual put option volume: GDDY SMMT FITB AUR TXRH VTRS MNST SATS KC TEM TWLO
-
Increasing unusual call option volume: EWW CRSR CENX BROS IAU TEM
-
Tempus AI stock downgraded by William Blair after massive rally
-
William Blair Downgrades Tempus AI Inc (TEM) to Market Perform
-
Increasing unusual put option volume: FMC EA HBAN TPX ICE EXE TKO BBAI MTCH TEM
-
Increasing unusual call option volume: DINO BCRX FMC ACB EA VSH TEM GPRO SAN JCI
-
TD Cowen Reinstates Tempus AI Inc (TEM) at Buy
-
Tempus AI (TEM) call put ratio 3.1 calls to 1 put into quarter results
-
Tempus AI (TEM) call put ratio 5.5 calls to 1 put with a focus on July 70 calls into quarter results
-
Genialis Advances Biomarker Discovery to Reduce Risk in Cancer Drug Development Targeting DNA Damage Response Pathways (TEM)
-
Increasing unusual put option volume: EWC EA YOU XLI EDR MLCO BTG HIMX VERU ALK TKO TEM
-
Tempus AI (TEM) call put ratio 3 calls to 1 put with as share price up 39%
-
Increasing unusual put option volume: LW FTAI WMB WEN XP FAST CFG RGTI CLMT IYR TEM
-
Tempus AI (TEM) Announces National Launch of olivia, its AI-enabled Personal Health Concierge App for Patients
-
Tempus AI (TEM) Announces the National Launch of FDA-Approved xT CDx Test
-
Tempus AI Inc (TEM) PT Lowered to $52 at Loop Capital
-
Tempus AI (TEM) Announces xH
-
Tempus AI (TEM) Announces Preliminary Fourth Quarter and Full Year 2024 Results
-
Tempus AI (TEM) Announces a Collaboration With Genialis to Develop RNA-Based Biomarker Algorithms
-
Tempus AI Inc (TEM) PT Raised to $70 at Piper Sandler
-
Stifel Downgrades Tempus AI Inc (TEM) to Hold
-
Tempus AI Inc (TEM) PT Raised to $56 at Needham
-
Tempus AI (TEM) to Acquire Ambry Genetics, Reports Q3
-
Avacta and Tempus (TEM) Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology
-
Tempus AI Inc (TEM) PT Raised to $57 at Loop Capital
-
Tempus AI (TEM) Announces Real World Data Collaboration with BioNTech (BNTX)
-
Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
-
Piper Sandler Starts Tempus AI Inc (TEM) at Neutral
-
Tempus AI, Inc (TEM) Reports Q2 Loss of $6.86; offers guidance
-
BofA Securities Starts Tempus AI Inc (TEM) at Buy
-
Wall Street starts Tempus AI coverage after IPO, shares climb
-
Loop Capital Starts Tempus AI Inc (TEM) at Buy
-
William Blair Starts Tempus AI Inc (TEM) at Outperform
-
Needham Starts Tempus AI Inc (TEM) at Buy
-
TD Cowen Starts Tempus AI Inc (TEM) at Buy, 'largest oncology Dx co.'
-
Morgan Stanley Starts Tempus AI Inc (TEM) at Overweight
-
JPMorgan Starts Tempus AI Inc (TEM) at Overweight

